N. Viñolas

发表

miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer.

Bernat Gel, E. Gallardo, A. Navarro, 2009, Carcinogenesis.

Tetrofosmin as predictors of tumour response.

J. Pavía, N. Viñolas, D. Fuster, 2003, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

OA13.05 NADIM Study: Updated Clinical Research and Outcomes

N. Viñolas, B. Massuti, M. Provencio, 2019, Journal of Thoracic Oncology.

Usefulness of Serum Tumor Markers, Including Progastrin-Releasing Peptide, in Patients with Lung Cancer: Correlation with Histology

N. Viñolas, R. Marrades, J. Ramírez, 2009, Tumor Biology.

Lung cancer and treatment in elderly patients: the Achilles Study.

R. Rosell, N. Viñolas, M. Provencio, 2009, Lung cancer.

Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.

D. Gandara, E. Felip, L. Paz-Ares, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Monitoring HOTTIP levels on extracellular vesicles for predicting recurrence in surgical non-small cell lung cancer patients

A. Navarro, N. Viñolas, R. Marrades, 2021, Translational oncology.

SEOM guidelines on thrombosis in cancer patients

N. Viñolas, D. Isla, A. Muñoz, 2011, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Serum anti-p53 antibodies and prognosis of patients with small-cell lung cancer.

N. Malats, F. Real, N. Viñolas, 1997, Journal of the National Cancer Institute.

Feasibility, tolerability, and efficacy of the concurrent addition of erlotinib to thoracic radiotherapy in locally advanced unresectable non-small-cell lung cancer: a Phase II trial

N. Viñolas, M. Dómine, Maite Martínez, 2016, OncoTargets and therapy.

Prognostic Significance of O6-Methylguanine-DNA Methyltransferase Determined by Promoter Hypermethylation and Immunohistochemical Expression in Anaplastic Gliomas

I. Ferrer, J. Acebes, N. Viñolas, 2005, Clinical Cancer Research.

Cancer diagnosis disclosure in a Spanish hospital.

N. Viñolas, J. Grau, J. Estapé, 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

Long Non-Coding RNA NANCI/NKX2-1 Duplex Impacts Prognosis in Stage I Non-Small-Cell Lung Cancer

A. Navarro, N. Viñolas, R. Marrades, 2020, Archivos de Bronconeumología (English Edition).

Long Non-Coding RNA NANCI/NKX2-1 Duplex Impacts Prognosis in Stage I Non-Small-Cell Lung Cancer.

A. Navarro, N. Viñolas, R. Marrades, 2020, Archivos de bronconeumologia.

The value of postoperative surveillance after radical surgery for colorectal cancer

N. Viñolas, A. Castells, J. Piqué, 1997 .

A randomized phase II study of pemetrexed versus pemetrexed plus erlotinib in second-line treatment for locally advanced or metastatic, nonsquamous NSCLC.

J. von Pawel, N. Viñolas, C. Dittrich, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Toxicity of small cell lung cancer treatment.

N. Viñolas, F. Casas, 2004, Hematology/oncology clinics of North America.

Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database

N. Viñolas, M. Provencio, P. Garrido, 2017, Clinical and Translational Oncology.

Lung Cancer in Women with a Family History of Cancer: The Spanish Female-specific Database WORLD07.

E. Felip, N. Viñolas, M. Provencio, 2016, Anticancer research.

Clinical significance of long non-coding RNA HOTTIP in early-stage non-small-cell lung cancer

A. Navarro, N. Viñolas, R. Marrades, 2019, BMC Pulmonary Medicine.

Multiplex RNA‐based detection of clinically relevant MET alterations in advanced non‐small cell lung cancer

R. Rosell, N. Viñolas, A. Prat, 2020, Molecular oncology.

Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.

N. Viñolas, R. Molina, X. Filella, 2005, Anticancer research.

Pro-Gastrin-Releasing Peptide in Patients with Benign and Malignant Diseases

N. Viñolas, R. Molina, X. Filella, 2004, Tumor Biology.

Assessment of the psychosocial and economic impact according to sex in non-small cell lung cancer patients: an exploratory longitudinal study

E. Felip, N. Viñolas, P. Garrido, 2020, BMC Psychology.

MA03.11 Trained Dogs Can Identify Malignant Pulmonary Nodules in Exhaled Gas

A. Agustí, N. Viñolas, R. Marrades, 2018, Journal of Thoracic Oncology.

Detection of occult breast cancer cells by amplification of CK19 mRNA by reverse transcriptase-polymerase chain reaction: role of surgical manipulation.

D. Colomer, P. Gascón, N. Viñolas, 2002, Anticancer research.

Prognostic implications of miR‐16 expression levels in resected non‐small‐cell lung cancer

E. Gallardo, A. Navarro, N. Viñolas, 2011, Journal of surgical oncology.

Neoadjuvant chemo-immunotherapy for the treatment of stage IIIA resectable non-small-cell lung cancer (NSCLC): A phase II multicenter exploratory study—Final data of patients who underwent surgical assessment.

N. Viñolas, B. Massuti, M. Provencio, 2019, Journal of Clinical Oncology.

Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)

Javier M. Martín-López, N. Viñolas, B. Massuti, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hodgkin's disease in external mammary lymph nodes.

E. Montserrat, N. Viñolas, C. Rozman, 1985, Annals of internal medicine.

Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain

J. Mayordomo, N. Viñolas, Andrés López, 2009, Current medical research and opinion.

Pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in early-stage NSCLC.

J. Mazières, N. Viñolas, M. Reck, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lymphocyte doubling time in chronic lymphocytic leukemia: an update of its prognostic significance.

E. Montserrat, N. Viñolas, C. Rozman, 1987, Blood cells.

"Smouldering" Chronic Lymphocytic Leukemia.

E. Montserrat, N. Viñolas, C. Rozman, 1991, Leukemia & lymphoma.

Natural history of chronic lymphocytic leukemia: on the progression and progression and prognosis of early clinical stages.

E. Montserrat, N. Viñolas, C. Rozman, 1988, Nouvelle revue francaise d'hematologie.

Recombinant alpha 2-interferon in the treatment of B chronic lymphocytic leukemia in early stages.

E. Montserrat, T. Gallart, N. Viñolas, 1988, Blood.

Serum immunoglobulins in B‐chronic lymphocytic leukemia. Natural history and prognostic significance

E. Montserrat, N. Viñolas, C. Rozman, 1988, Cancer.

Characterization of the MicroRNA Cargo of Extracellular Vesicles Isolated from a Pulmonary Tumor-Draining Vein Identifies miR-203a-3p as a Relapse Biomarker for Resected Non-Small Cell Lung Cancer

A. Navarro, N. Viñolas, R. Marrades, 2022, International journal of molecular sciences.

Phlegmasia cerulea dolens and multiple recurrent thrombotic events as the presenting feature of EML4-ALK translocated non-small cell lung cancer

N. Viñolas, N. Reguart, C. Font, 2016 .

CHOP vs. ProMACE‐CytaBOM in the treatment of aggressive non‐Hodgkin's lymphomas: long‐term results of a multicenter randomized trial

A. López-Guillermo, E. Montserrat, J. Garcia-conde, 1996, European journal of haematology.

Exosome Analysis in Tumor-Draining Pulmonary Vein Identifies NSCLC Patients with Higher Risk of Relapse after Curative Surgery

A. Navarro, N. Viñolas, R. Marrades, 2019, Cancers.

Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy

N. Viñolas, B. Massuti, V. Calvo, 2022, Journal for ImmunoTherapy of Cancer.

ANALYSIS OF DIFFERENT PROPOSALS TO DEFINE “ SMOULDERING ” CLL “ Smouldering ” CLL concept

E. Montserrat, N. Viñolas, C. Rozman, 2007 .

Adjuvant treatment in stage I and II malignant melanoma: a randomized trial between chemoimmunotherapy and immunotherapy.

N. Viñolas, J. Palou, A. Vilalta, 1991, Dermatologica.

Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial.

A. Carrato, E. Felip, R. Rosell, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Spanish patterns of care for 3D radiotherapy in non-small-cell lung cancer.

N. Viñolas, A. Sánchez-Reyes, A. Biete, 2006, International journal of radiation oncology, biology, physics.

Role of the epithelial-mesenchymal transition-related circular RNA, circ-10720, in non-small-cell lung cancer

A. Navarro, N. Viñolas, R. Marrades, 2021, Translational lung cancer research.

Phase II trial of cisplatinum and etoposide in brain metastases of solid tumors

B. Mellado, N. Viñolas, F. Graus, 1997, Journal of Neuro-Oncology.

Combined assay of adenosine deaminase, purine nucleoside phosphorylase, and lactate dehydrogenase in the early clinical evaluation of B‐chronic lymphocytic leukemia

E. Montserrat, D. Colomer, T. Gallart, 1988, American journal of hematology.

miR-141 and miR-200c as Markers of Overall Survival in Early Stage Non-Small Cell Lung Cancer Adenocarcinoma

A. Navarro, N. Viñolas, R. Marrades, 2014, PloS one.

Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance

Ciril Rozman, E. Montserrat, N. Viñolas, 1986, British journal of haematology.

C. Fan, J. Parker, E. Felip, 2017, Cancer research.

MicroRNAs Expressed during Lung Cancer Development Are Expressed in Human Pseudoglandular Lung Embryogenesis

Carlos Agustí, C. Agustí, A. Navarro, 2009, Oncology.

Single nucleotide polymorphisms in tobacco metabolism and DNA repair genes and prognosis in resected non-small-cell lung cancer.

J. Gimferrer, A. Navarro, N. Viñolas, 2011, The Journal of surgical research.

Prospective Evaluation of Single Nucleotide Variants by Two Different Technologies in Paraffin Samples of Advanced Non-Small Cell Lung Cancer Patients

P. Jares, N. Viñolas, N. Reguart, 2020, Diagnostics.

Identification of ALK, ROS1, and RET Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non-Small-Cell Lung Cancer Patients.

F. López-Ríos, R. Rosell, N. Viñolas, 2017, Clinical chemistry.

The significance of PIWI family expression in human lung embryogenesis and non-small cell lung cancer

A. Navarro, N. Viñolas, R. Marrades, 2015, Oncotarget.

Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival.

N. Malats, F. Real, W. Mason, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Extracellular Vesicle lincRNA-p21 Expression in Tumor-Draining Pulmonary Vein Defines Prognosis in NSCLC and Modulates Endothelial Cell Behavior

A. Navarro, N. Viñolas, R. Marrades, 2020, Cancers.

Hematological Toxicity in Lung Cancer

N. Viñolas, F. Casas, F. Ferrer, 2011 .

Mitomycin C as an adjuvant treatment to resected gastric cancer. A 10-year follow-up.

N. Viñolas, C. Pera, J. Estapé, 1991, Annals of surgery.

EBUS-TBNA Cytological Samples for Comprehensive Molecular Testing in Non–Small Cell Lung Cancer

P. Jares, C. Agustí, Marcelo Sánchez, 2021, Cancers.

LincRNA‐p21 Impacts Prognosis in Resected Non–Small Cell Lung Cancer Patients through Angiogenesis Regulation

A. Navarro, N. Viñolas, R. Marrades, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Assessment of a Combined Panel of Six Serum Tumor Markers for Lung Cancer.

A. Agustí, N. Viñolas, R. Marrades, 2016, American journal of respiratory and critical care medicine.

Tumor Markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in Patients with Non-Small Cell Lung Cancer as an Aid in Histological Diagnosis and Prognosis

N. Viñolas, R. Molina, V. Moreno, 2003, Tumor Biology.

Sex differences in non-small cell lung cancer (NSCLC) patients (p) participating in Spanish Lung Cancer Group (SLCG) trials

R. Rosell, N. Viñolas, P. Garrido, 2007 .

MicroRNAs in human lung cancer and human lung embryogenesis: P2-004

E. Gallardo, A. Navarro, N. Viñolas, 2007 .

Assessment of ALK Status by FISH on 1000 Spanish Non-Small Cell Lung Cancer Patients

M. Salido, J. Bosch-Barrera, J. Albanell, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Lung Cancer OncoGuia

J. Lloreta, M. Alejo, E. Felip, 2009, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine.

E. Felip, R. Rosell, N. Viñolas, 2011, Lung cancer.

A Pilot Study to Evaluate Early Predictive Value of Thorax Perfusion-CT in Advanced NSCLC

Marcelo Sánchez, M. Benegas, I. Vollmer, 2021, Cancers.

Pleural effusion is a negative prognostic factor for immunotherapy in patients with non-small cell lung cancer (NSCLC): The pluie study.

D. Planchard, N. Viñolas, N. Reguart, 2021, Lung cancer.

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial.

I. Wistuba, N. Viñolas, B. Massuti, 2020, The Lancet. Oncology.

Oral vinorelbine versus etoposide with cisplatin and chemo-radiation as treatment in patients with stage III non-small cell lung cancer: A randomized phase II (RENO study).

N. Viñolas, B. Massuti, M. Provencio, 2019, Lung cancer.

Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisions

M. Catalán, R. Rosell, N. Viñolas, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical Activity of Afatinib in Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Spanish Retrospective Multicenter Study.

S. Cedrés, N. Viñolas, M. Dómine, 2020, Clinical lung cancer.

Lung Cancer in Never-Smoking Women: A Sub-Analysis of the Spanish Female-Specific Database WORLD07

E. Felip, N. Viñolas, M. Provencio, 2017, Cancer investigation.

A consensus statement on the gender perspective in lung cancer

J. Borrás, F. López-Ríos, E. Felip, 2017, Clinical and Translational Oncology.

Lung cancer in women: an overview with special focus on Spanish women

E. Felip, N. Viñolas, P. Garrido, 2014, Clinical and Translational Oncology.

Chronic oral etoposide in non-small cell lung carcinoma.

C. Agustí, N. Viñolas, J. Ramírez, 1992, European journal of cancer.

Intracavitary oxytetracycline in malignant pericardial tamponade.

N. Viñolas, J. Estapé, J. Grau, 1992, Oncology.

A Dual Role for KRT81: A miR-SNP Associated with Recurrence in Non-Small-Cell Lung Cancer and a Novel Marker of Squamous Cell Lung Carcinoma

J. Gimferrer, P. Gascón, A. Navarro, 2011, PloS one.

Cell-free DNA concentration and fragment size fraction correlate with FDG PET/CT-derived parameters in NSCLC patients

I. Vollmer, N. Viñolas, N. Reguart, 2021, European Journal of Nuclear Medicine and Molecular Imaging.

Mucins CA 125, CA 19.9, CA 15.3 and TAG-72.3 as Tumor Markers in Patients with Lung Cancer: Comparison with CYFRA 21-1, CEA, SCC and NSE

N. Viñolas, R. Marrades, J. Ramírez, 2008, Tumor Biology.

Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum.

Antonio Nieto, Mariano Provencio, Bartomeu Massuti, 2012, Lung cancer.

Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy

I. Wistuba, N. Viñolas, B. Massuti, 2021, Clinical Cancer Research.

Usefulness of Two Independent DNA and RNA Tissue-Based Multiplex Assays for the Routine Care of Advanced NSCLC Patients

P. Jares, Marcelo Sánchez, I. Vollmer, 2020, Cancers.

Severe aplastic anaemia following hepatitis A.

N. Viñolas, A. Palomeque, R. Jiménez, 1986, Acta haematologica.

A randomized Phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II Non-Small-Cell Lung Cancer.

Tuan S. Nguyen, W. Engel-Riedel, J. Mazières, 2015, Lung cancer.

Low miR-145 and high miR-367 are associated with unfavourable prognosis in resected nonsmall cell lung cancer

J. Gimferrer, A. Navarro, N. Viñolas, 2012, European Respiratory Journal.

"Spontaneous" complete remissions in chronic lymphocytic leukemia: report of three cases and review of the literature.

E. Montserrat, T. Gallart, N. Viñolas, 1987, Blood cells.

Long-Term Results of a Phase II Trial of Induction Paclitaxel-Carboplatin Followed by Concurrent Radiation Therapy and Weekly Paclitaxel and Consolidation Paclitaxel-Carboplatin in Stage III Non-small Cell Lung Cancer

B. Jeremic, Marcelo Sánchez, N. Viñolas, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Integrating concurrent navelbine and cisplatin to hyperfractionated radiotherapy in locally advanced non-small cell lung cancer patients treated with induction and consolidation chemotherapy: feasibility and activity results.

P. Gascón, N. Viñolas, N. Reguart, 2004, Lung cancer.

SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015

N. Viñolas, B. Massuti, R. García-Campelo, 2015, Clinical and Translational Oncology.

P2.04-10 Biomarkers of Pathological Response on Neo-Adjuvant Chemo-Immunotherapy Treatment for Resectable Stage IIIA NSCLC Patients

N. Viñolas, B. Massuti, M. Provencio, 2019, Journal of Thoracic Oncology.

Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial

N. Viñolas, B. Massuti, M. Provencio, 2021, Journal for ImmunoTherapy of Cancer.

Age: a critical factor in cancer management. A prospective comparative study of 400 patients.

Grau, N. Viñolas, M. Muñoz, 1999, Age and ageing.

Chronic oral etoposide in advanced breast cancer

B. Mellado, N. Viñolas, J. Estapé, 2004, Cancer Chemotherapy and Pharmacology.

Pre-irradiation semi-intensive chemotherapy with carboplatin and cyclophosphamide in malignant glioma: a phase II study

N. Viñolas, S. Villà, F. Graus, 2002, Anti-cancer drugs.

Prognostic implication of clinical, radiologic, and pathologic features in patients with anaplastic gliomas

J. Acebes, N. Viñolas, I. Ferrer, 2003, Cancer.

Efficacy of radiotherapy for malignant gliomas in elderly patients.

A. Martinez, N. Viñolas, V. Moreno, 1998, International journal of radiation oncology, biology, physics.

Does gender matter in glioblastoma?

Yolanda Blanco, Laura Oleaga, Teresa Boget, 2011, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Carboplatin, methotrexate, vinblastine and epirubicin (Carbo-MVE) for transitional cell bladder carcinoma.

N. Viñolas, A. Alcaraz, J. Mallafré, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types

M. Juan, B. Mellado, J. Llovet, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Improvement in performance status after erythropoietin treatment in lung cancer patients undergoing concurrent chemoradiotherapy.

J. Gimferrer, N. Viñolas, B. Farrús, 2003, International journal of radiation oncology, biology, physics.

Metastatic carcinoma of the breast resembling early gastric carcinoma.

N. Viñolas, C. Romagosa, R. Miquel, 2001, Mayo Clinic proceedings.

Cisplatin plus oral vinorelbine as first-line treatment for advanced non-small-cell lung cancer: a prospective study confirming that the day-8 hemogram is unnecessary

N. Viñolas, M. Provencio, M. Dómine, 2013, Clinical and Translational Oncology.

miR-34 a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer

E. Gallardo, A. Navarro, N. Viñolas, 2009 .

Radiochemotherapy in special populations with limited-disease small - cell lung cancer and locally advanced non-small-cell lung cancer

N. Viñolas, F. Casas, I. Ríos, 2012 .

Sleeve lobectomy after induction chemoradiotherapy.

N. Viñolas, N. Reguart, L. Molins, 2012, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

OA20.02 Pre-Treatment Levels of ctDNA for Long-Term Survival Prediction in Stage IIIA NSCLC Treated With Neoadjuvant Chemo-Immunotherapy

N. Viñolas, B. Massuti, M. Provencio, 2021, Journal of Thoracic Oncology.

OA20.01 Long Term Survival in Operable Stage Iiia Nsclc Patients Treated With Neoadjuvant Nivolumab Plus Chemotherapy - Nadim Study

N. Viñolas, B. Massuti, M. Provencio, 2021, Journal of Thoracic Oncology.

Is invasive mediastinal staging necessary in intermediate risk patients with negative PET/CT?

Marcelo Sánchez, N. Viñolas, R. Marrades, 2020, Journal of thoracic disease.

Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial

I. Wistuba, N. Viñolas, B. Massuti, 2021, Clinical and translational medicine.

NKX2–1 expression as a prognostic marker in early-stage non-small-cell lung cancer

A. Navarro, N. Viñolas, R. Marrades, 2017, BMC Pulmonary Medicine.

YKT6 expression, exosome release, and survival in non-small cell lung cancer

A. Navarro, N. Viñolas, R. Marrades, 2016, Oncotarget.

Lung cancer in Spanish women: The WORLD07 project

Mariano Provencio, E. Felip, N. Viñolas, 2018, European journal of cancer care.

Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial.

N. Viñolas, S. Villà, F. Graus, 2005, International journal of radiation oncology, biology, physics.

Venous Thromboembolism in Cancer Patients : Comparison of Lung Cancer Patients to Other Solid Tumor Patients in a Prospective Observational Study

P. Gascón, N. Viñolas, N. Reguart, 2013 .

LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology

E. Felip, J. Bosch-Barrera, J. Palacios, 2021, Cancer medicine.

Molecular characterization of advanced non-small cell lung cancer patients by cfDNA analysis: experience from routine laboratory practice

P. Jares, N. Viñolas, N. Reguart, 2021, Journal of thoracic disease.

MA03.08 Impact of COVID-19 Pandemic in the Diagnosis and Prognosis of Lung Cancer

N. Viñolas, A. Prat, N. Reguart, 2021, Journal of Thoracic Oncology.

ERCC1 mRNA-based randomized phase III trial of docetaxel (doc) doublets with cisplatin (cis) or gemcitabine (gem) in stage IV non-small-cell lung cancer (NSCLC) patients (p)

E. Felip, R. Rosell, N. Viñolas, 2005 .

Correction to: Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study

M. Juan, N. Viñolas, A. Prat, 2023, Cancer Immunology, Immunotherapy.

A phase II study of bemcentinib (BGB324), a first-in-class highly selective AXL inhibitor, with pembrolizumab in pts with advanced NSCLC: OS for stage I and preliminary stage II efficacy.

E. Schmidt, R. Holt, E. Felip, 2019, Journal of Clinical Oncology.

MA03.06 Efficacy Results of Selective AXL Inhibitor Bemcentinib with Pembrolizumab Following Chemotherapy in Patients with NSCLC

E. Schmidt, R. Holt, E. Felip, 2019, Journal of Thoracic Oncology.

Prevalence of incidental pathogenic germline variants detected in cfDNA in patients with oncogene-driven non-small cell lung cancer.

N. Viñolas, A. Prat, N. Reguart, 2022, Journal of Clinical Oncology.

The role of sex and gender in the diagnosis and treatment of lung cancer: the 6th ICAPEM Annual Symposium.

Michael A. Rodriguez, A. Ruano-Raviña, E. Felip, 2023, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Feasibility and tolerability of the addition of erlotinib to 3D thoracic radiotherapy (RT) in patients (p) with unresectable NSCLC: A prospective randomized phase II study

N. Viñolas, M. Dómine, F. Casas, 2008 .

Concomitant and adjuvant temozolomide (TMZ) and whole brain irradiation (WBI) on patients affected with brain metastases (BM): a randomized multicentric phase II trial

N. Viñolas, S. Villà, F. Graus, 2003 .

Trained dogs can identify malignant solitary pulmonary nodules in exhaled gas.

A. Agustí, N. Viñolas, R. Marrades, 2019, Lung cancer.

SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015

N. Viñolas, R. García-Campelo, E. Nadal, 2015, Clinical and Translational Oncology.

Randomized phase II trial (RENO): Efficacy results of oral vinorelbine or etoposide combined with cisplatin in chemo-radiotherapy treatment of locally advanced NSCLC (LA-NSCLC)—SLCG 10/02.

N. Viñolas, M. Provencio, R. Peñas, 2016 .

A randomised phase II study of pemetrexed versus pemetrexed+erlotinib as second-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer.

J. von Pawel, N. Viñolas, C. Dittrich, 2014, European journal of cancer.